Outset Medical Appoints Industry Veteran Kevin O鈥橞oyle to its Board of Directors
Outset Medical (Nasdaq: OM) has appointed healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee, replacing Dale E. Jones who has stepped down. O'Boyle brings over 20 years of healthcare leadership experience, having served as CFO of several public companies and as a board director for 6 public medical device companies.
O'Boyle's extensive board experience includes positions at Nevro Corp., GenMark Diagnostics (as Chairman), Sientra, Wright Medical Group, Zeltiq Aesthetics, and Durata Therapeutics. He previously served as CFO of Advanced Biohealing and NuVasive, and currently serves on the board of Carlsmed, a private spine surgery solutions company.
Outset Medical (Nasdaq: OM) ha nominato il veterano del settore sanitario Kevin O'Boyle nel suo Consiglio di Amministrazione e come presidente del Comitato di Revisione Contabile, sostituendo Dale E. Jones che si 猫 dimesso. O'Boyle vanta oltre 20 anni di esperienza nella leadership sanitaria, avendo ricoperto il ruolo di CFO in diverse societ脿 pubbliche e come membro del consiglio di amministrazione in 6 aziende pubbliche nel settore dei dispositivi medici.
L'ampia esperienza di O'Boyle nei consigli include posizioni presso Nevro Corp., GenMark Diagnostics (come Presidente), Sientra, Wright Medical Group, Zeltiq Aesthetics e Durata Therapeutics. In passato 猫 stato CFO di Advanced Biohealing e NuVasive e attualmente fa parte del consiglio di Carlsmed, una societ脿 privata specializzata in soluzioni per la chirurgia spinale.
Outset Medical (Nasdaq: OM) ha nombrado al veterano de la industria sanitaria Kevin O'Boyle como miembro de su Junta Directiva y presidente de su Comit茅 de Auditor铆a, reemplazando a Dale E. Jones, quien renunci贸. O'Boyle aporta m谩s de 20 a帽os de experiencia en liderazgo sanitario, habiendo sido CFO de varias empresas p煤blicas y director en el consejo de 6 compa帽铆as p煤blicas de dispositivos m茅dicos.
La amplia experiencia de O'Boyle en juntas incluye cargos en Nevro Corp., GenMark Diagnostics (como presidente), Sientra, Wright Medical Group, Zeltiq Aesthetics y Durata Therapeutics. Anteriormente fue CFO de Advanced Biohealing y NuVasive, y actualmente forma parte del consejo de Carlsmed, una empresa privada de soluciones para cirug铆a de columna.
Outset Medical(雮橃姢雼�: OM)電� 鞚橂 鞐呹硠 氩犿厡霝戩澑 Kevin O'Boyle鞚� 鞚挫偓須� 氅る矂鞚挫瀽 臧愳偓鞙勳洂須� 鞚橃灔鞙茧 鞛勲獏頄堨溂氅�, 鞚措姅 靷瀯頃� Dale E. Jones毳� 雽�觳错晿電� 鞛愲Μ鞛呺媹雼�. O'Boyle鞚� 20雲� 鞚挫儊鞚� 鞚橂 毽崝鞁� 瓴巾棙鞚� 臧�歆�瓿� 鞛堨溂氅�, 鞐煬 靸侅灔 須岇偓鞚� CFO鞕� 6臧滌潣 靸侅灔 鞚橂旮瓣赴 須岇偓 鞚挫偓搿� 頇滊彊頃挫檾鞀惦媹雼�.
O'Boyle鞚� 韽創鞚� 鞚挫偓須� 瓴巾棙鞐愲姅 Nevro Corp., GenMark Diagnostics(鞚橃灔), Sientra, Wright Medical Group, Zeltiq Aesthetics, Durata Therapeutics 霌膘澊 韽暔霅╇媹雼�. 攴鸽姅 鞚挫爠鞐� Advanced Biohealing瓿� NuVasive鞚� CFO毳� 鞐瀯頄堨溂氅� 順勳灛電� 觳欖稊 靾橃垹 靻旊（靺橃潉 鞝滉车頃橂姅 靷劋 須岇偓 Carlsmed鞚� 鞚挫偓搿� 頇滊彊 欷戩瀰雼堧嫟.
Outset Medical (Nasdaq : OM) a nomm茅 le v茅t茅ran de l'industrie de la sant茅 Kevin O'Boyle 脿 son conseil d'administration et en tant que pr茅sident de son comit茅 d'audit, en remplacement de Dale E. Jones qui a d茅missionn茅. O'Boyle apporte plus de 20 ans d'exp茅rience en leadership dans le secteur de la sant茅, ayant 茅t茅 directeur financier (CFO) de plusieurs entreprises publiques et administrateur dans 6 soci茅t茅s publiques de dispositifs m茅dicaux.
La vaste exp茅rience d'O'Boyle au sein des conseils d'administration inclut des postes chez Nevro Corp., GenMark Diagnostics (en tant que pr茅sident), Sientra, Wright Medical Group, Zeltiq Aesthetics et Durata Therapeutics. Il a pr茅c茅demment occup茅 le poste de CFO chez Advanced Biohealing et NuVasive, et si猫ge actuellement au conseil d'administration de Carlsmed, une entreprise priv茅e sp茅cialis茅e dans les solutions de chirurgie de la colonne vert茅brale.
Outset Medical (Nasdaq: OM) hat den erfahrenen Branchenexperten Kevin O'Boyle in seinen Vorstand berufen und ihn zum Vorsitzenden des Pr眉fungsausschusses ernannt. Er ersetzt Dale E. Jones, der zur眉ckgetreten ist. O'Boyle bringt 眉ber 20 Jahre F眉hrungserfahrung im Gesundheitswesen mit und war CFO mehrerer b枚rsennotierter Unternehmen sowie Vorstandsmitglied bei sechs b枚rsennotierten Medizinger盲tefirmen.
O'Boyles umfangreiche Erfahrung in Aufsichtsr盲ten umfasst Positionen bei Nevro Corp., GenMark Diagnostics (als Vorsitzender), Sientra, Wright Medical Group, Zeltiq Aesthetics und Durata Therapeutics. Zuvor war er CFO von Advanced Biohealing und NuVasive und ist derzeit Vorstandsmitglied bei Carlsmed, einem privaten Unternehmen f眉r Wirbels盲ulenchirurgie-L枚sungen.
- None.
- None.
SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (鈥淥utset鈥�), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O鈥橞oyle to its Board of Directors and as chair of its Audit Committee. With Mr. O鈥橞oyle鈥檚 appointment, the company also announced that Dale E. Jones has stepped down from the Board.
鈥淜evin鈥檚 over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies,鈥� said Leslie Trigg, Chair and CEO. 鈥淗is expertise in capital equipment and recurring revenue business models similar to Outset will help guide the company through its next stage of growth.
鈥淚 also want to thank Dale for his innumerable contributions to Outset during a critical period for the company. The experience, guidance and insights he brought to the board will have a lasting impact as we continue to build for the future.鈥�
Mr. O鈥橞oyle served on the board of directors of Nevro Corp. from March 2019 through April 2025 when the company was acquired by Globus Medical, Inc. He also served as Chairman of the GenMark Diagnostics board until its acquisition by Roche in May 2021. Additionally, Mr. O鈥橞oyle served on the boards of Sientra, Inc., Wright Medical Group, Zeltiq Aesthetics, and Durata Therapeutics. He currently serves on the board of Carlsmed, a private company specializing in personalized spine surgery solutions. Previously, he was Senior Vice President and Chief Financial Officer of Advanced Biohealing Inc., a medical device company, from December 2010 until it was acquired in July 2011. Prior to that, Mr. O鈥橞oyle served as Chief Financial Officer of NuVasive, Inc. from January 2003 to December 2009. Earlier in his career, Mr. O鈥橞oyle served in various leadership positions during his six years with ChromaVision Medical Systems, Inc. He holds a B.S. in Accounting from the Rochester Institute of Technology.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo庐 Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Contact
Jim Mazzola
Investor Relations
FAQ
Who is Kevin O'Boyle and what is his new role at Outset Medical (OM)?
What is Kevin O'Boyle's previous experience in the healthcare industry?
Who did Kevin O'Boyle replace on Outset Medical's board?
What is Outset Medical's (OM) business focus?
